tellimustine

Tellimustine is a medication used in the treatment of certain types of cancer, specifically non-Hodgkin lymphoma and mantle cell lymphoma. It is a purine analog, which means it is structurally similar to the natural purine bases found in DNA. Tellimustine works by inhibiting DNA synthesis, leading to cell death in rapidly dividing cancer cells. This mechanism makes it particularly effective against cancers that have a high rate of cell division.

The drug is administered intravenously and typically requires hospitalization for the initial treatment. It is usually given in combination with other chemotherapy agents to enhance its effectiveness and reduce the risk of resistance. Common side effects include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include low blood cell counts, which can increase the risk of infections and bleeding.

Tellimustine was approved by the U.S. Food and Drug Administration (FDA) in 2016. It is marketed under the brand name Teclast. The drug's efficacy and safety profile have been studied in clinical trials, and it has shown promising results in the treatment of certain types of lymphoma. However, like all chemotherapy drugs, tellimustine carries risks and should be used under the guidance of a healthcare professional.